Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.

Neal JW, Sequist LV.

J Clin Oncol. 2012 Jun 20;30(18):2280-2. doi: 10.1200/JCO.2011.41.0860. Epub 2012 Apr 16. No abstract available.

PMID:
22508823
2.

[Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer].

Zhou CC, Deng XF.

Zhonghua Jie He He Hu Xi Za Zhi. 2007 Feb;30(2):138-40. Review. Chinese. No abstract available.

PMID:
17445479
3.

Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.

Kotsakis A, Georgoulias V.

Expert Opin Pharmacother. 2010 Oct;11(14):2363-89. doi: 10.1517/14656566.2010.498581. Review.

PMID:
20586711
4.

Molecular selection of patients for first-line treatment of advanced non-small-cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime time.

Shepherd FA.

J Clin Oncol. 2008 May 20;26(15):2426-7. doi: 10.1200/JCO.2007.15.4286. Epub 2008 May 5. No abstract available.

PMID:
18458043
5.

Novel targeted therapies for non-small cell lung cancer.

Smith PW, Denlinger CE, Jones DR.

Thorac Surg Clin. 2006 Nov;16(4):353-66. Review.

PMID:
17240823
6.

[Targeted therapies and radiation therapy in non-small cell lung cancer].

Rivera S, Quéro L, Wong Hee Kam S, Maylin C, Deutsch E, Hennequin C.

Cancer Radiother. 2011 Oct;15(6-7):527-35. doi: 10.1016/j.canrad.2011.07.234. Epub 2011 Aug 31. Review. French.

PMID:
21885318
7.

Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.

Mukherji D, Spicer J.

Expert Opin Investig Drugs. 2009 Mar;18(3):293-301. doi: 10.1517/13543780902762843 . Review.

PMID:
19243280
8.

The role of EGFR inhibitors in nonsmall cell lung cancer.

Ciardiello F, De Vita F, Orditura M, Tortora G.

Curr Opin Oncol. 2004 Mar;16(2):130-5. Review.

PMID:
15075904
9.

Targeted therapies and non-small-cell lung cancer: work in progress?

Gridelli C.

Curr Opin Oncol. 2006 Mar;18(2):132-4. Review. No abstract available.

PMID:
16462181
10.

What phase III trials are needed to improve the treatment of advanced non-small-cell lung cancer?

Saijo N.

Nat Clin Pract Oncol. 2005 Jun;2(6):275. No abstract available.

PMID:
16264964
11.
12.
13.

Clinical targeting of VEGF and EGFR effective in non-small cell lung cancer.

[No authors listed]

Cancer Biol Ther. 2004 Jul;3(7):588-9. No abstract available.

PMID:
15751163
14.

Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier.

Sangha R, Lara PN Jr, Mack PC, Gandara DR.

Curr Opin Oncol. 2009 Mar;21(2):116-23. doi: 10.1097/CCO.0b013e3283210489. Review.

PMID:
19532012
15.

The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.

Gridelli C, Rossi A, Maione P.

Crit Rev Oncol Hematol. 2008 Oct;68(1):29-36. doi: 10.1016/j.critrevonc.2008.03.002. Epub 2008 Apr 18. Review.

PMID:
18424067
16.
17.

Targeted therapies in the treatment of non small cell lung cancer: reality and hopes.

Gridelli C.

Curr Opin Oncol. 2004 Mar;16(2):126-9. Review. No abstract available.

PMID:
15075903
18.
19.

Cetuximab: potential role as first-line treatment for advanced non-small cell lung cancer.

Pirker R.

Clin Adv Hematol Oncol. 2008 Oct;6(10):735-6. No abstract available.

PMID:
18997663
20.

[Biological therapy in non-small-cell lung cancer (NSCLC)].

Souquet PJ.

Rev Pneumol Clin. 2004 Nov;60(5 Pt 3):4S53-4S56. Review. French. No abstract available.

PMID:
15687996

Supplemental Content

Support Center